Cargando…

Potent bromodomain and extraterminal domain inhibitor JAB-8263 suppresses MYC expression and exerts anti-tumor activity in colorectal cancer models

BACKGROUND: The overexpression of the MYC gene plays an important role in the occurrence, development and evolution of colorectal cancer (CRC). Bromodomain and extraterminal domain (BET) inhibitors can decrease the function BET by recognizing acetylated lysine residues, thereby downregulating the ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xin-Mo, Xia, Shao-You, Long, Wei, Li, Hai-Jun, Yang, Gui-Qun, Sun, Wen, Li, Song-Yan, Du, Xiao-Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2023
Materias:	Basic Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994054/ https://www.ncbi.nlm.nih.gov/pubmed/36908321 http://dx.doi.org/10.4251/wjgo.v15.i2.332

Ejemplares similares

Validation of Bromodomain and Extraterminal proteins as therapeutic targets in neurofibromatosis type 2
por: Doherty, Joanne, et al.
Publicado: (2022)

Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours
por: Mu, Jianfeng, et al.
Publicado: (2020)

Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases
por: Morgado-Pascual, Jose Luis, et al.
Publicado: (2019)

The bromodomain and extraterminal domain inhibitor bromosporine synergistically reactivates latent HIV-1 in latently infected cells
por: Pan, Hanyu, et al.
Publicado: (2017)

Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy
por: Wang, Zhi-Qiang, et al.
Publicado: (2023)

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2017)

Bromodomain and Extraterminal Domain (BET) Protein Inhibition Hinders Glioblastoma Progression by Inducing Autophagy-Dependent Differentiation
por: Colardo, Mayra, et al.
Publicado: (2023)

Regulation of Cell Plasticity by Bromodomain and Extraterminal Domain (BET) Proteins: A New Perspective in Glioblastoma Therapy
por: Gargano, Deborah, et al.
Publicado: (2023)

Bromo‐ and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma
por: Liu, Chen, et al.
Publicado: (2020)

Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma
por: Chen, Ye, et al.
Publicado: (2019)

Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, “window-of-opportunity” study
por: Moreno, Victor, et al.
Publicado: (2022)

Bromodomain and Extraterminal (BET) Protein Inhibition Restores Redox Balance and Inhibits Myofibroblast Activation
por: Stock, Carmel J. W., et al.
Publicado: (2019)

Inhibition of bromodomain extraterminal histone readers alleviates skin fibrosis in experimental models of scleroderma
por: Vichaikul, Sirapa, et al.
Publicado: (2022)

Suppression of YAP/TAZ-Notch1-NICD axis by bromodomain and extraterminal protein inhibition impairs liver regeneration
por: Liu, Chen, et al.
Publicado: (2019)

Inhibition of Bromodomain and Extraterminal Domain (BET) Proteins by JQ1 Unravels a Novel Epigenetic Modulation to Control Lipid Homeostasis
por: Tonini, Claudia, et al.
Publicado: (2020)

Bromodomain and extraterminal inhibitors block the Epstein-Barr virus lytic cycle at two distinct steps
por: Keck, Kristin M., et al.
Publicado: (2017)

The Role of Bromodomain and Extraterminal (BET) Proteins in Controlling the Phagocytic Activity of Microglia In Vitro: Relevance to Alzheimer’s Disease
por: Matuszewska, Marta, et al.
Publicado: (2022)

Epigenetic readers and lung cancer: the rs2427964C>T variant of the bromodomain and extraterminal domain gene BRD3 is associated with poorer survival outcome in NSCLC
por: Lee, Jang Hyuck, et al.
Publicado: (2021)

Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations
por: Wang, Qianqian, et al.
Publicado: (2017)

Prolonged Response of a Patient with Relapsed Acute Myeloid Leukemia to a Novel Oral Bromodomain Extraterminal Inhibitor (BETi)
por: Chang Muñoz, Meilen, et al.
Publicado: (2020)

Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro
por: Gilham, Dean, et al.
Publicado: (2021)

Jab
por: Boggon, Adam
Publicado: (2022)

Bromodomain and extraterminal (BET) protein inhibitor, apabetalone, reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro
por: Gilham, D, et al.
Publicado: (2021)

BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial
por: Hilton, John, et al.
Publicado: (2022)

Free flu jabs for dentists jabs axed by NHS England
Publicado: (2022)

Double-bromo and extraterminal (BET) domain proteins regulate dendrite morphology and mechanosensory function
por: Bagley, Joshua A., et al.
Publicado: (2014)

Structural Mechanism of the Oxygenase JMJD6 Recognition by the Extraterminal (ET) Domain of BRD4
por: Konuma, Tsuyoshi, et al.
Publicado: (2017)

A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia
por: Borthakur, Gautam, et al.
Publicado: (2021)

Bromodomain and extraterminal (BET) protein inhibition of IgG/IgE production in murine B cells is counter‐balanced by a strong Th2 bias
por: Dalloul, Zeinab, et al.
Publicado: (2021)

The Impact of the No Jab No Play and No Jab No Pay Legislation in Australia: A Scoping Review
por: Burns, Sharyn, et al.
Publicado: (2023)

The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs
por: Liu, Pei Y., et al.
Publicado: (2016)

Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition
por: Graziani, Vittoria, et al.
Publicado: (2023)

Clinicopathological Significance of Expression of Tspan-1, Jab1 and p27 in Human Hepatocellular Carcinoma
por: Chen, Li, et al.
Publicado: (2010)

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
por: Bolin, Sara, et al.
Publicado: (2018)

Free flu jab from dentists
por: Yeung, C. A.
Publicado: (2020)

India Unburdening the Pandemic: Jabs and Talks
por: Basu, Eilene, et al.
Publicado: (2023)

77232 The role of the bromodomain and extra-terminal motif (BET) family of proteins in head and neck cancer tumorigenic phenotype
por: Sample, Reilly A., et al.
Publicado: (2021)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
por: Li, Weiping, et al.
Publicado: (2019)

BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc
por: Li, Ning, et al.
Publicado: (2018)

Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands
por: Hewings, David S., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4c4vlofv56tjv429agj8gips5h